Brief: Hutchmed (China) Announces NMPA Conditional Approval For Atled (Fantegratinib) In China
BRIEF-Hutchmed (China) Announces NMPA Conditional Approval For Atled (Fantegratinib) In China Aug 28 (Reuters) - HUTCHMED (China) Ltd 0013.HK:
ANNOUNCES NMPA CONDITIONAL APPROVAL FOR ATLED (FANTEGRATINIB) IN CHINA
Further company coverage: 0013.HK
((Reuters.Briefs@thomsonreuters.com;))